Abstract
The phase III randomized Pragmatica-Lung trial, comparing therapies for late-stage or recurrent non-small cell lung cancer, has eased eligibility criteria, simplified primary objectives, and limited data gathering requirements. Investigators hope that the design will speed accrual, expand patient eligibility and diversity, and ease administrative burdens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
